2-溴-1-(4-羟基-3-甲氧基苯基)乙酮 | 69638-06-8

• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 2-溴-1-(4-羟基-3-甲氧基苯基)乙酮
• 英文名称: 2-bromo-1-(4-hydroxy-3-methoxyphenyl)ethanone
• CAS: 69638-06-8
• 化学式: C₉H₉BrO₃
• 分子量: 245.073
• InChiKey: SDTPFVAZAREICN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  13
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  46.5
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 危险等级：
  IRRITANT
• 海关编码：
  2914700090
• 包装等级：
  III
• 危险类别：
  8
• 危险性防范说明：
  P264,P270,P271,P280,P303+P361+P353,P304+P340,P305+P351+P338,P310,P330,P331,P363,P403+P233,P501
• 危险品运输编号：
  1759
• 危险性描述：
  H302,H314
• 储存条件：
  2-8°C，惰性气体

反应信息

• 作为反应物：
  描述：

  2-溴-1-(4-羟基-3-甲氧基苯基)乙酮 在 水 、 1,8-二氮杂双环[5.4.0]十一碳-7-烯 、 三氟乙酸 作用下， 以 1,4-二氧六环 为溶剂， 反应 16.0h， 生成 高香草酸
  参考文献：
  名称：

  新的光触发：扩展了对羟基苯甲酰pi-pi的吸收范围。

  摘要：

  [等式-见正文]已经研究了用两种兴奋性γ-氨基酸（L-谷氨酸和γ-氨基丁酸）在4-羟基苯甲酰基（pHP）可光除去的保护基上引入3-甲氧基或3,5-二甲氧基取代基的方法。 （GABA）。这些取代基显着扩展了pHP发色团的吸收范围，例如2a，b的吸收带的尾部延伸超过400 nm，远远超出了芳香族氨基酸和核苷酸的吸收。辐照释放出氨基酸的速率常数约为10（7）s（-）（1），外观效率（Phi（app））为0.03-0.04。光产物是通过pHP激发三重态形成的，主要是光还原和光水解的产物。1a，b也重新排列为苯乙酸3。

  DOI：

  10.1021/ol005856n
• 作为产物：
  描述：

  香草乙酮 在 copper(I) bromide 作用下， 以 乙醇 为溶剂， 生成 2-溴-1-(4-羟基-3-甲氧基苯基)乙酮
  参考文献：
  名称：

  Hydrogenolysis of lignosulfonate into phenols over heterogeneous nickel catalysts

  摘要：

  我们报告了一种利用异相镍催化剂将木质磺酸盐转化为酚类的策略。芳香烃–烷基键（C–O–C）和羟基（–OH）分别被氢化为酚和烷烃，而不会干扰芳烃。该催化剂基于一种自然丰富的元素，且可回收和重复使用。

  DOI：

  10.1039/c2cc31414b

文献信息

• Nucleus-Independent Chemical Shift (NICS) as a Criterion for the Design of New Antifungal Benzofuranones
  作者：María de los Ángeles Zermeño-Macías、Marco Martín González-Chávez、Francisco Méndez、Arlette Richaud、Rodolfo González-Chávez、Luis Enrique Ojeda-Fuentes、Perla del Carmen Niño-Moreno、Roberto Martínez

  DOI：10.3390/molecules26165078

  日期：——

  aromaticity criterion to evaluate the antifungal activity of two series of indol-4-ones. A linear regression analysis of NICS and antifungal activity showed that both tested variables were significantly related (p < 0.05); when aromaticity increased, the antifungal activity decreased for series I and increased for series II. To verify the validity of the obtained equations, a new set of 44 benzofuran-4-ones

  吴等人的断言。芳香性可能对分子设计有相当大的影响，促使我们使用核独立化学位移 (NICS) 作为芳香性标准来评估两个系列的 indol-4-one 的抗真菌活性。NICS 和抗真菌活性的线性回归分析表明，两个测试变量显着相关（p< 0.05); 当芳香性增加时，系列 I 的抗真菌活性降低，系列 II 的抗真菌活性增加。为了验证所得到方程的有效性，通过用氧取代 indol-4-ones 中的五元环的氮原子，设计了一组新的 44 benzofuran-4-ones。计算了苯并呋喃-4-酮的 NICS(0) 和 NICS(1)，并使用前面的方程来预测它们的生物活性。一组 10 苯并呋喃 4-ones 合成并在八种人类致病真菌中进行测试，显示了方程的有效性。对于光滑念珠菌、克柔念珠菌和吉列念珠菌与化合物15 -酵母菌的最低抑菌浓度 (MIC) 为 31.25 µg·mL –132，15 - 15和15
• Catechol derivatives
  申请人：Hoffmann-La Roche Inc.

  公开号：US05236952A1

  公开（公告）日：1993-08-17

  Catechol derivatives of the formula ##STR1## wherein Ra, Rb and Rc have the significance given herein, the ester and ether derivatives thereof which are hydrolyzable under physiological conditions and the pharmaceutically acceptable salts thereof are described and possess valuable pharmacological properties. In particular, they inhibit the enzyme catechol-O-methyltransferase (COMT), a soluble, magnesium-dependent enzyme which catalyses the transference of the methyl group of S-adensoylmethionine to a catechol substrate, whereby the corresponding methyl ethers are formed. Suitable substrates which can be O-methylated by COMT and which can thus be deactivated are, for example, extraneuornal catecholamines and exogeneously-administered therapeutically active substances having a catechol structure. Formula Ia above embraces not only compounds which form part of the invention, but also known compounds; the compounds which form part of the invention can be prepared according to known methods.

  公式##STR1##中的儿茶酚衍生物，其中Ra、Rb和Rc具有本文中给出的含义，以及在生理条件下可水解的酯和醚衍生物及其药学上可接受的盐已被描述，并具有有价值的药理特性。特别是，它们抑制儿茶酚-O-甲基转移酶(COMT)这种可溶性、依赖镁的酶，该酶催化S-腺苷甲硫氨酸的甲基基团转移到儿茶酚底物上，从而形成相应的甲基醚。可被COMT进行O-甲基化并因此被失活的适当底物包括，例如，外源性儿茶酚胺和具有儿茶酚结构的外源性给药的治疗活性物质。上述公式Ia不仅包括发明的一部分化合物，还包括已知的化合物；构成发明一部分的化合物可以按照已知方法制备。
• PHENYLIMIDAZOLE COMPOUNDS
  申请人：Shibutani Tadao

  公开号：US20110275823A1

  公开（公告）日：2011-11-10

  [Object] To provide a pharmaceutical product (chemotherapeutic agent) effective in the prevention and treatment of hyperlipidemia, obesity, etc. [Solving Means] A phenylimidazole compound represented by the following General Formula (1): wherein, R 1 represents a hydrogen atom, a phenyl lower alkyl group optionally having a substituent, or a pyridyl lower alkyl group optionally having a substituent, and the benzene ring and the pyridine ring are optionally substituted with 1 or 2 substituents selected from the group consisting of halogen atoms, cyano group and halogen-substituted lower alkyl groups. One of R 2 and R 3 represents a hydrogen atom and the other represents a lower alkoxy group. R 4 represents a phenyl group optionally having a substituent. R 5 and R 6 are the same or different, and represent a hydrogen atom or a lower alkyl group. R 7 and R 8 are the same or different, and represent a hydrogen atom or a lower alkoxy group. However, when R 1 represents an unsubstituted phenyl lower alkyl group, R 2 represents a lower alkoxy group, R 3 represents a hydrogen atom, R 4 represents a phenyl group optionally having a substituent, and R 5 represents a hydrogen atom, R 6 is not a hydrogen atom.

  提供一种在预防和治疗高脂血症、肥胖等方面有效的药物产品（化疗药物）。 解决方法是通过以下一般式（1）所代表的苯基咪唑化合物： 其中，R1代表氢原子、苯基较低烷基基团（可选地带有取代基）或吡啶基较低烷基基团（可选地带有取代基），苯环和吡啶环可选地带有来自卤原子、氰基和卤代较低烷基基团的1或2个取代基。R2和R3中的一个代表氢原子，另一个代表较低烷氧基团。R4代表可选地带有取代基的苯基团。R5和R6相同或不同，代表氢原子或较低烷基基团。R7和R8相同或不同，代表氢原子或较低烷氧基团。但是，当R1代表未取代的苯基较低烷基基团时，R2代表较低烷氧基团，R3代表氢原子，R4代表可选地带有取代基的苯基团，R5代表氢原子时，R6不是氢原子。
• [EN] 2-PHENYL OR 2-HETARYL IMIDAZOL[1,2-a]PYRIDINE DERIVATIVES<br/>[FR] DÉRIVÉS DE 2-PHÉNYL- OU 2-HÉTARYL-IMIDAZOL[1,2-A]PYRIDINE
  申请人：HOFFMANN LA ROCHE

  公开号：WO2014177458A1

  公开（公告）日：2014-11-06

  The invention relates to compounds of formulas I and II, formula I or formula II wherein R1 is hydrogen, lower alkyl, lower alkoxy, halogen, S-lower alkyl, lower alkoxy substituted by halogen, di-lower alkyl amino, C(O)O-lower alkyl, lower alkyl substituted by hydroxy or hydroxy; R2 is hydrogen, lower alkyl, halogen, lower alkoxy, S-lower alkyl, lower alkoxy substituted by halogen, O(CH2)2-lower alkoxy substituted by halogen, di-lower alkyl amino, alkyl amino, NH-lower alkyl substituted by halogen, N(lower alkyl)-benzyl, lower alkyl substituted by hydroxy, heterocycloalkyl optionally substituted by halogen, CH2-lower alkoxy, CH2-lower alkoxy substituted by halogen or hydroxy; or R1 and R2 form together with the carbon atoms to which they are attached a ring containing -OCH2CH2O-, OCH2O-, OCH2CH2CH2O- or -NHC(O)CH2O-; R3 is hydrogen or lower alkoxy; R4 is hydrogen or lower alkyl; R5 is lower alkyl, cycloalkyl, lower alkyl substituted by hydroxy or lower alkyl substituted by halogen; or R4 and R5 form together with the nitrogen atom to which they are attached a ring containing -CH2CH2CHRCH2CH2-, -CH2CHRCH2CH2-, -CH2CH2OCH2CH2-, -CH2CH2NR'CH2CH2-, CH2CHR- or -CH2CH2CH2-; wherein R is hydrogen, halogen, lower alkyl, lower alkoxy or lower alkyl substituted by halogen; R' is lower alkyl substituted by halogen; Ra is hydrogen or H; Rb is hydrogen, hydroxy or 3H; R6 is hydrogen, halogen or lower alkyl; HetAr is selected from the group consisting of thiophenyl, furanyl, thiozolyl, benzofuranyl, pyrazolyl, benzoimidazolyl or pyridinyl; n is 1 or 2; or to a pharmaceutically acceptable acid addition salt, to a racemic mixture or to its corresponding enantiomer and/or optical isomers thereof. The present compounds are suitable as imaging tool, which will improve diagnosis by identifying potential patients with excess of tau aggregates in the brain, which may be likely to develop Alzheimer's disease.

  本发明涉及式I和式II的化合物，式I或式II中，R1为氢、低级烷基、低级烷氧基、卤素、S-低级烷基、卤素取代的低级烷氧基、二-低级烷基氨基、C(O)O-低级烷基、羟基取代的低级烷基或羟基；R2为氢、低级烷基、卤素、低级烷氧基、S-低级烷基、卤素取代的低级烷氧基、O(CH2)2-卤素取代的低级烷氧基、二-低级烷基氨基、烷基氨基、NH-卤素取代的低级烷基、N(低级烷基)-苄基、羟基取代的低级烷基、任选卤素取代的杂环烷基、CH2-低级烷氧基、CH2-卤素或羟基取代的低级烷氧基；或者R1和R2与其所连接的碳原子一起形成含有-OCH2CH2O-、OCH2O-、OCH2CH2CH2O-或-NHC(O)CH2O-的环；R3为氢或低级烷氧基；R4为氢或低级烷基；R5为低级烷基、环烷基、羟基取代的低级烷基或卤素取代的低级烷基；或者R4和R5与其所连接的氮原子一起形成含有-CH2CH2CHRCH2CH2-、-CH2CHRCH2CH2-、-CH2CH2OCH2CH2-、-CH2CH2NR'CH2CH2-、CH2CHR-或-CH2CH2CH2-的环；其中R为氢、卤素、低级烷基、低级烷氧基或卤素取代的低级烷基；R'为卤素取代的低级烷基；Ra为氢或H；Rb为氢、羟基或3H；R6为氢、卤素或低级烷基；HetAr选自噻吩基、呋喃基、噻唑基、苯并呋喃基、吡唑基、苯并咪唑基或吡啶基；n为1或2；或为药学上可接受的酸加成盐、外消旋混合物或其相应的对映体和/或光学异构体。本发明的化合物适合作为成像工具，通过识别大脑中tau聚集体过量的潜在患者，将有助于改善诊断，这些患者可能发展为阿尔茨海默病。
• <i>p</i>-Hydroxyphenacyl photoremovable protecting groups — Robust photochemistry despite substituent diversity
  作者：Richard S. Givens、Kenneth Stensrud、Peter G. Conrad、Abraham L. Yousef、Chamani Perera、Sanjeewa N. Senadheera、Dominik Heger、Jakob Wirz

  DOI：10.1139/v10-143

  日期：2011.2

  A broadly based investigation of the effects of a diverse array of substituents on the photochemical rearrangement of p-hydroxyphenacyl esters has demonstrated that common substituents such as F, MeO, CN, CO₂R, CONH₂, and CH₃have little effect on the rate and quantum efficiencies for the photo-Favorskii rearrangement and the release of the acid leaving group or on the lifetimes of the reactive triplet state. A decrease in the quantum yields across all substituents was observed for the release and rearrangement when the photolyses were carried out in buffered aqueous media at pHs that exceeded the ground-state pK_aof the chromophore where the conjugate base is the predominant form. Otherwise, substituents have only a very modest effect on the photoreaction of these robust chromophores.

  一项关于各种取代基对对羟基苯乙酯光化学重排影响的广泛研究表明，常见取代基（如 F、MeO、CN、CO2R、CONH2 和 CH3）对光-Favorskii 重排和酸离去基团释放的速率和量子效率影响很小，对反应三重态的寿命影响也很小。当光解在缓冲水介质中进行时，pH 值超过发色团的基态 pKao（其中共轭碱是主要形式），则释放和重排的量子产率在所有取代基中都会降低。否则，取代基对这些坚固发色团的光反应影响很小。